Source:http://linkedlifedata.com/resource/pubmed/id/11548224
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2001-9-10
|
pubmed:abstractText |
Glucosamine sulfate is a drug used for the treatment of osteoarthritis (OA), based on its pharmacological and metabolic activities on the cartilage and chondrocytes, complemented by mild anti-inflammatory properties and a favorable pharmacokinetic profile. The aim of this study was to define the activity and safety of glucosamine sulfate on the symptoms of patients with OA, using a multicenter, randomized, placebo-controlled, double-blind, parallel-group study design. The study included 252 outpatients with OA of the knee (Lequesne's criteria), radiological stage between I and III, and Lequesne's severity index of at least 4 points and symptoms for at least 6 months. Patients were treated with either placebo or oral glucosamine sulfate 500 mg t.i.d. for 4 weeks, with weekly, with weekly clinic visits. Responders to treatment were defined as patients with a reduction of at least 3 points in the Lequesne's index with a positive overall assessment by the investigator. The Lequesne's index was 10.6 +/- 0.45 S.E.M. points in both groups at the start of the study. This decreased to 7.45 +/- 0.5 points in the treatment group (average 3.2) and 8.4 +/- 0.4 points in the placebo group (average 2.2) (P < 0.05, Student's t-test). The responder rate in the evaluable patients was 55% with glucosamine (N = 120) vs 38% with placebo (N = 121). These proportions were 52% vs 37% in an intention-to-treat analysis (P = 0.014 and 0.016, respectively; Fisher's Exact Test). The medications were well tolerated throughout the study, with no difference between the glucosamine and placebo treated groups. It is concluded that glucosamine sulfate may be a safe and effective symptomatic Slow Acting Drug for OA.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1063-4584
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
2
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
51-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:11548224-Administration, Oral,
pubmed-meshheading:11548224-Adult,
pubmed-meshheading:11548224-Aged,
pubmed-meshheading:11548224-Double-Blind Method,
pubmed-meshheading:11548224-Female,
pubmed-meshheading:11548224-Glucosamine,
pubmed-meshheading:11548224-Humans,
pubmed-meshheading:11548224-Male,
pubmed-meshheading:11548224-Middle Aged,
pubmed-meshheading:11548224-Movement Disorders,
pubmed-meshheading:11548224-Osteoarthritis, Knee,
pubmed-meshheading:11548224-Pain,
pubmed-meshheading:11548224-Treatment Outcome
|
pubmed:year |
1994
|
pubmed:articleTitle |
Glucosamine sulfate in osteoarthritis of the knee.
|
pubmed:affiliation |
Department of Orthopedics-Evangelisches Waldkrankenhaus, Berlin, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|